Published in Cancer Weekly, June 10th, 2008
"In this model, treatment with Ads expressing Fms-like tyrosine kinase 3 ligand (FIt3L), in combination with Ad-HSV1-TK improves the survival rate to similar to 70% and induces systemic antitumor immunity. We hypothesized that the growth of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly